Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Cédric Le May
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
Related publications
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
European Scientific Journal ESJ
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin
Pharmaceutics
Pharmaceutical Science
Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model
Yonago Acta Medica
Medicine
Clinical Risk Factors Predicting Genital Fungal Infections With Sodium–glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit
Primary Care Diabetes
Internal Medicine
Nutrition
Endocrinology
Dietetics
Metabolism
Diabetes
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery
Lijecnicki Vjesnik
Medicine
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
Journal of Investigative Medicine High Impact Case Reports
Risk
Epidemiology
Reliability
Safety
Safety Research
Quality
Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
The Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin Does Not Prolong QT Interval in a Thorough QT (TQT) Study
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
